These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 12594453

  • 1. Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF).
    Gheorghiade M, Gattis WA, Adams KF, Jaffe AS, O'Connor CM, Pilot Randomized Study of Nesiritide versus Dobutamine in Heart Failure, Duke University Cooperative Cardiovascular Studies Investigators.
    Am Heart J; 2003 Feb; 145(2 Suppl):S55-7. PubMed ID: 12594453
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC.
    Mehra MR, McCluskey T, Barr M, Bourge RC, Jessup ML, Mancini D, Radovancevic B, Rayburn B, Taylor DO, Lilly-Hersley J, Linde P.
    Am Heart J; 2007 Jun; 153(6):932-40. PubMed ID: 17540193
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure.
    Aronson D, Burger AJ.
    Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294
    [Abstract] [Full Text] [Related]

  • 6. B-type natriuretic peptide: from bench to bedside.
    Adams KF, Mathur VS, Gheorghiade M.
    Am Heart J; 2003 Feb; 145(2 Suppl):S34-46. PubMed ID: 12594450
    [No Abstract] [Full Text] [Related]

  • 7. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
    Arnold LM, Crouch MA, Carroll NV, Oinonen MJ.
    Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
    [Abstract] [Full Text] [Related]

  • 8. Observation unit treatment of heart failure with nesiritide: results from the proaction trial.
    Peacock WF, Holland R, Gyarmathy R, Dunbar L, Klapholz M, Horton DP, de Lissovoy G, Emerman CL.
    J Emerg Med; 2005 Oct; 29(3):243-52. PubMed ID: 16183441
    [Abstract] [Full Text] [Related]

  • 9. Nesiritide for decompensated congestive heart failure.
    Med Lett Drugs Ther; 2001 Nov 12; 43(1118):100-1. PubMed ID: 11707752
    [No Abstract] [Full Text] [Related]

  • 10. Nesiritide Therapy Is Associated With Better Clinical Outcomes Than Dobutamine Therapy in Heart Failure.
    Kong LG, Wang CL, Zhao D, Wang B.
    Am J Ther; 2017 Nov 12; 24(2):e181-e188. PubMed ID: 26164026
    [Abstract] [Full Text] [Related]

  • 11. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure.
    Gerhard T, Zineh I, Winterstein AG, Hartzema AG.
    Pharmacotherapy; 2006 Jan 12; 26(1):34-43. PubMed ID: 16509026
    [Abstract] [Full Text] [Related]

  • 12. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A.
    J Am Coll Cardiol; 2009 Jun 23; 53(25):2343-8. PubMed ID: 19539144
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rationale and design of the enoximone clinical trials program.
    Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR.
    J Card Fail; 2005 Dec 23; 11(9):659-69. PubMed ID: 16360960
    [Abstract] [Full Text] [Related]

  • 15. Critical review and recommendations for nesiritide use in the emergency department.
    Collins SP, Hinckley WR, Storrow AB.
    J Emerg Med; 2005 Oct 23; 29(3):317-29. PubMed ID: 16183453
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of serial home infusions of nesiritide for advanced heart failure.
    Chung ES, Menon SG, Daly KA, Atkinson J, Peterson T, Robertson R, Ibanez K, Kereiakes DJ.
    Am J Cardiol; 2006 May 01; 97(9):1370-3. PubMed ID: 16635613
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Digoxin in heart failure.
    Chadwell M, French L.
    J Fam Pract; 1997 May 01; 44(5):442. PubMed ID: 9152256
    [No Abstract] [Full Text] [Related]

  • 19. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure.
    de Lissovoy G, Stier DM, Ciesla G, Munger M, Burger AJ.
    Am J Cardiol; 2003 Sep 01; 92(5):631-3. PubMed ID: 12943895
    [Abstract] [Full Text] [Related]

  • 20. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
    Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM.
    Am Heart J; 2009 Feb 01; 157(2):271-7. PubMed ID: 19185633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.